B.C. biotech company says, despite interim approva

2022-04-05
  • Detail
B.C. biotech company saysThe impact we have o, despite interim approval, provinces won't use its COVID-19 treatment | CBC News - Today News Post News Today || Canada News |

The CEO of a B.C.?biotechnology company says the treatment his firm has developed for COVID-19 is sitting on shelves while people continue to die, despite it being approved for use by Health Canada in the fall.?

“Canada was quick to authorize itThe horizon, and they seem to be helping our southern neighbours.. The federal government moved quickly to procure it. So we signed a procurement agreement and bought doses back in November,” Dr. Carl HansenBelarusFebruary 2021 – AFP, co-founder and CEO of Vancouver-based?AbCellera, told CBC News Network’s Power & Politics.?

“But because of some decisions that happened at the provincial and territorial level, through committees that are making decisions on recommendations of use, thus far this treatment has been used in almost no one in Canada.”

Bamlanivimab is an antibody therapy that Hansen says acts as a synthetic immunity. He said it can be given to patients in the early stages of COVID-19 to reduce the possibility of developing severe illness and death by up to 80 per cent.?The amusement park has been administering shots at its vaccination clinic for almost a month.?

Copyright © 2011 JIN SHI